We demonstrated that TRPM2 contribute to the invasion and metastasis of GC via Akt-mediated EMT, and suggested TRPM2 inhibition as a potential therapeutic approach to hamper GC metastasis and improve GC treatment. The gene discussed is AKT1; the disease is gastric cancer.